| Literature DB >> 17014395 |
Abstract
Insulin aspart, an analogue of human insulin, which is approved for use in people with diabetes, is more rapidly absorbed and achieves higher plasma concentrations than human soluble insulin following subcutaneous injection. Hence, it has a faster and more effective glucose-lowering action, with superior control of postprandial hyperglycaemia compared with human soluble insulin. Its shorter duration of action makes interprandial and nocturnal hypoglycaemia less of a problem than with human soluble insulin. Insulin aspart is approved for use in continuous subcutaneous infusion and offers a valuable treatment option during pregnancy.Entities:
Mesh:
Substances:
Year: 2006 PMID: 17014395 DOI: 10.1517/17425255.2.5.793
Source DB: PubMed Journal: Expert Opin Drug Metab Toxicol ISSN: 1742-5255 Impact factor: 4.481